CASI Pharmaceuticals (ENM) Stock Price & Analysis
ENM Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 2.21M
- Enterprise Value
- CHF 40.23M
- Total Cash (Recent Filing)
- CHF 3.77M
- Total Debt (Recent Filing)
- CHF 40.50M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
CID-103 Clinical Advancement
Progressing CID-103 into clinical testing and completing dose-escalation enrollment creates potential for a broader future pipeline beyond current commercial products. These milestones support strategic focus and, if later validated, could expand CASI’s addressable transplant rejection and autoimmune markets.
Non-dilutive Strategic Funding
The Alesta stake sale provides immediate non-dilutive cash while preserving CASI’s licensed rights to CID-103. That combination can strengthen funding for clinical development without issuing shares and leaves possible milestone receipts as an additional source of future support.
Improved Cost And Loss Profile
Lower operating expenses and a narrower first-half loss show some progress in aligning the cost base with current commercial scale. Sustaining this discipline could extend available funding and improve operating leverage as CASI advances its pipeline, although profitability remains distant.
Bears Say
Persistent Revenue Contraction
Three consecutive years of shrinking revenue indicate sustained commercialization headwinds rather than a temporary quarterly fluctuation. A smaller revenue base limits internally generated funding, weakens operating leverage, and increases the importance of successful product execution and pipeline advancement.
Severe Operating Losses And Cash Burn
Very large operating and net losses, combined with continuing negative operating cash flow, show that the current business does not fund its own operations. Persistent cash consumption can constrain clinical investment and keep CASI dependent on financing or asset monetization.
Negative Equity And Strained Balance Sheet
Negative equity and higher debt reduce financial flexibility and make the capital structure more vulnerable to refinancing pressure. With assets also contracting, CASI has less balance-sheet capacity to absorb setbacks or fund development internally, increasing dilution risk over the medium term.
ENM FAQ
What is CASI Pharmaceuticals’s market cap?
When is CASI Pharmaceuticals’s upcoming earnings report date?
How were CASI Pharmaceuticals’s earnings last quarter?
Is CASI Pharmaceuticals overvalued?
Does CASI Pharmaceuticals pay dividends?
What is CASI Pharmaceuticals’s EPS estimate?
What happened to CASI Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CASI Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The company's offerings include EVOMELA, an intravenous formulation of melphalan, which serves as a conditioning treatment before stem cell transplantation and as palliative care for patients with multiple myeloma. Its hematology/oncology pipeline is robust, featuring CNCT19, an investigative autologous CD19 CAR-T product; BI-1206, a novel anti-FcγRIIB antibody designed for treating solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, an innovative VCP/p97 inhibitor targeting valosin-containing protein (VCP)/p97 pathways crucial for protein homeostasis, DNA damage response, and cellular stress in various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with diverse indications, including its use as a conditioning regimen prior to certain allogeneic hematopoietic stem cell transplants. CASI Pharmaceuticals maintains licensing agreements with entities such as Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., primarily for the development and commercialization of its commercial product, EVOMELA. The company was founded in 1991 and is headquartered in Beijing, People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David A. Cory
- Employees
- 214
- Website
- www.casipharmaceuticals.com
- Address
- 1701-1702, China Central Office Tower 1, Beijing, BE, 100025, CN
